antitumor efficacy of 345enve a transcriptionally retargeted and vstat120expressing oncolytic virus here we describe the construction and testing of a novel herpes simplex virus type 1 hsv1 derived oncolytic virus ov 345enve viral icp345 expressed by nestin promotor and vstat120 expressing for the treatment of cancer this virus showed significant gliomaspecific killing and antiangiogenic effects in vitro and in vivo treatment of subcutaneous and intracranial gliomabearing mice with 345enve showed a significant increase in median survival of mice in four different glioma models histology and dynamic contrastenhanced magnetic resonance imaging dcemri revealed reduced microvessel density mvd and increased tumoral necrosis in 345envetreated tumor tissue compared to control ovtreated tumor tissue collectively these results describe the construction efficacy and impact on tumor microenvironment of a transcriptionally driven ov armed with vstat120 gene expression these preclinical results will facilitate future clinical testing of 345enve